WELLESLEY, Mass., Aug. 2 /PRNewswire-FirstCall/ -- Coley Pharmaceutical Group, Inc. , today announced that Robert L. Bratzler, Ph.D., President and Chief Executive Officer, will provide a corporate presentation at the 26th Annual Canaccord Adams Summer Seminar in Boston on Tuesday, August 8, 2006 at 11:30 a.m. Eastern Time.
Interested parties may access a webcast of the presentation by visiting the Coley Pharmaceutical Group website at http://www.coleypharma.com. A replay of the webcast will be archived on the “Investor Events” page in the Investor Center section of the Coley website for two weeks, until August 22, 2006.
About Coley Pharmaceutical Group
Coley Pharmaceutical Group, Inc. is an international biopharmaceutical company, headquartered in Wellesley, Massachusetts, USA, that discovers and develops TLR Therapeutics(TM), a new class of investigational drug candidates that direct the human immune system to fight cancers, infectious diseases, asthma and allergy. Coley has established a pipeline of four TLR Therapeutic product candidates currently advancing through clinical development either independently or with partners, and additional product candidates in preclinical development. Coley has product development, research and license agreements with Pfizer, sanofi-aventis, Novartis Vaccines & Diagnostics (formerly Chiron), GlaxoSmithKline and the United States government. For further information on Coley Pharmaceutical Group please visit http://www.coleypharma.com.
Coley Pharmaceutical Group, Inc.
CONTACT: Charles H. Abdalian, Jr., Senior Vice President and CFO of ColeyPharmaceutical Group, Inc., +1-781-431-9044, cabdalian@coleypharma.com; orKaren L. Bergman, +1-650-575-1509, kbergman@bccpartners.com, or MichelleCorral, +1-415-794-8662, mcorral@bccpartners.com, both of BCC Partners forColey Pharmaceutical Group, Inc.
Web site: http://www.coleypharma.com/
